Larry Bornstein
Psychiatry · Everett, WANPI 1548343577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $561,941 of the $662,741 with a category attached, or 84.8%. Teva Pharmaceuticals USA, Inc. accounts for 79.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $241,622 and has fallen 88.6% since, to $27,435 in 2025. Among psychiatry clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 802 payments — averaging $826.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$527K
- Neurocrine Biosciences, Inc.$114K
- Otsuka America Pharmaceutical, Inc.$16K
- Sunovion Pharmaceuticals Inc.$4K
- Johnson & Johnson$2K
- Alkermes, Inc.$120
- plus $27 from 1 others
What the payments were for
- Consulting fees$5,7011%
- Speaking & faculty fees$561,94185%
- Travel & lodging$80,63412%
- Food & beverage$14,4652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 554 | $526,549 |
| Neurocrine Biosciences, Inc. | 200 | $113,776 |
| Otsuka America Pharmaceutical, Inc. | 33 | $16,392 |
| Sunovion Pharmaceuticals Inc. | 8 | $3,818 |
| Johnson & Johnson | 5 | $2,059 |
| Alkermes, Inc. | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$267,080
- UZEDY$176,481
- INGREZZA$110,917
- Austedo XR$74,442
- ABILIFY MAINTENA$15,566
- LATUDA$3,751
- INVEGA SUSTENNA$2,040
- INVEGA TRINZA$1,360
- REXULTI$802
- LYBALVI$480
How this compares
$662,741 in reported general payments places this provider in the 95th percentile of 576 psychiatry providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 16 | $23,725 |
| Divalproex Sodium | 27 | $4,172 |
| Clozapine | 28 | $3,788 |
| Oxcarbazepine | 13 | $1,448 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $1,332 |
| Lurasidone Hcl | 14 | $631 |
| Quetiapine Fumarate | 30 | $627 |
| Olanzapine | 11 | $483 |
| Sertraline Hcl | 24 | $438 |
| Trazodone Hcl | 28 | $426 |
| Prazosin Hcl | 16 | $412 |
| Buspirone Hcl | 34 | $322 |
| Aripiprazole | 21 | $275 |
| Hydroxyzine Hcl | 15 | $227 |
| Duloxetine Hcl | 11 | $219 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Everett
- Jeffrey HansenVancouver$2.8M
- Chester RobachinskiSeattle$1.1M
- Matthew BogoyasYakima$500K
- Pablo ProanoSeattle$112K
- David DunnerMercer Island$79K
- Jesse McClellandSeattle$39K
- Douglas WornellFox Island$31K
- Lina FineSeattle$30K
- John JaccardSpokane$16K
- Cara ErkutMercer Island$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.